CN116615462A - 抗体构建体的表达技术 - Google Patents

抗体构建体的表达技术 Download PDF

Info

Publication number
CN116615462A
CN116615462A CN202180077498.XA CN202180077498A CN116615462A CN 116615462 A CN116615462 A CN 116615462A CN 202180077498 A CN202180077498 A CN 202180077498A CN 116615462 A CN116615462 A CN 116615462A
Authority
CN
China
Prior art keywords
heavy chain
antibody
peptide
nucleic acid
antibody construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180077498.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·凯卢尔
M·赫斯林
A·里特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN116615462A publication Critical patent/CN116615462A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180077498.XA 2020-11-23 2021-11-22 抗体构建体的表达技术 Pending CN116615462A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117379P 2020-11-23 2020-11-23
US63/117,379 2020-11-23
PCT/IB2021/060796 WO2022107090A1 (en) 2020-11-23 2021-11-22 Expression technology for antibody constructs

Publications (1)

Publication Number Publication Date
CN116615462A true CN116615462A (zh) 2023-08-18

Family

ID=78819584

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180077498.XA Pending CN116615462A (zh) 2020-11-23 2021-11-22 抗体构建体的表达技术

Country Status (5)

Country Link
US (1) US20250282894A1 (enExample)
EP (1) EP4247857A1 (enExample)
JP (1) JP2023550459A (enExample)
CN (1) CN116615462A (enExample)
WO (1) WO2022107090A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402253B (zh) * 2023-08-02 2024-08-23 南京大学 一种抗哇巴因的纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003106B2 (en) * 2002-03-13 2011-08-23 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
ES2546086T3 (es) 2007-12-21 2015-09-18 Novartis Ag Sistema de selección en un cultivo de células eucariotas basado en un gen receptor de folato unido a la membrana
PT3027646T (pt) 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
CN111499753B (zh) * 2014-03-03 2022-10-21 高雄医学大学 双功能抗体及其用途
CR20160519A (es) * 2014-05-13 2017-01-27 The Trustees Of The Univ Of Pennysylvania Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation

Also Published As

Publication number Publication date
US20250282894A1 (en) 2025-09-11
JP2023550459A (ja) 2023-12-01
WO2022107090A1 (en) 2022-05-27
EP4247857A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
JP7744391B2 (ja) 抗ｖｅｇｆタンパク質組成物及びその製造方法
US20220213500A1 (en) Expression Process
US10508154B2 (en) Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20200216553A1 (en) Method for producing multispecific antibodies
RU2716977C2 (ru) Новые селективные векторы и способы селекции эукариотических клеток-хозяев
US20210047392A1 (en) Method for the production of immunoglobulin single variable domains
KR20150076160A (ko) 발현 서열
EP3155013B1 (en) Method for selecting antibodies with modified fcrn interaction
TWI911155B (zh) 藉由多肽鏈交換活化之治療性多特異性多肽
NO331375B1 (no) DNA-molekyl kodende for sekretérbare peptider, protein, mulitkopivektor, plasmid, vertscelle, fremgangsmate for fermentering av proteiner og fremstilling av insulin
US20250282894A1 (en) Expression technology for antibody constructs
CN110777148B (zh) 用于表达fgf-2的dna序列和制备fgf-2的方法
CA2928927A1 (en) Use of peptidylglycine alpha-amidating monooxigenase (pam) for c-terminal amidation
JP2015535427A (ja) ポリペプチドを高収量で発現するための最適化発現カセット
EP2832854A1 (en) Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
RU2780629C1 (ru) Способ получения мультиспецифических антител
WO2025077816A1 (zh) 载体对与宿主细胞和高表达细胞株的构建方法
HK40068105A (en) Methods of manufacturing therapeutic proteins
HK40016750A (en) Optimization of dna sequence for fgf-2 expression and method for production of fgf-2
HK40016750B (en) Optimization of dna sequence for fgf-2 expression and method for production of fgf-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination